REG - LungLife AI, INC - Notice of Results

LungLife AIAnnouncement

15/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240815:nRSO5072Aa&default-theme=true

RNS Number : 5072A  LungLife AI, INC  15 August 2024

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Notice of Results

Investor Briefing

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the
early detection of lung cancer, will announce its unaudited half-year report
for the six months ended 30 June 2024 on Thursday 22 August 2024.

 

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial
Officer, will be hosting a live online presentation relating to the half-year
report via the Investor Meet Company platform at 5pm (BST) on Thursday 22
August 2024.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am (BST) the day before the meeting or at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
LUNGLIFE AI, INC via:
https://www.investormeetcompany.com/lunglife-ai-inc/register-investor
(https://www.investormeetcompany.com/lunglife-ai-inc/register-investor)

 

(https://www.investormeetcompany.com/lunglife-ai-inc/register-investor)
Investors who already follow LUNGLIFE AI, INC on the Investor Meet Company
platform will automatically be invited.

 

A recording of the presentation and a PDF of the slides used will also be
available on the LungLife website: https://lunglifeai.com/investors/
(https://lunglifeai.com/investors/)

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          investors@lunglifeai.com
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Lydia Zychowska / Sara Wallace

 Goodbody (Joint Broker)                                   Tel: +44 (0) 20 3841 6202

 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSFAFALELSEEA